Clinical trialPhase 1Completed

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

NCT01181245 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Finished, no results posted
Phase: Phase 1
Status: Completed
Study type: Interventional
Start: December 2008
Expected end: June 2014
Enrollment: 50 participants
Sites: 7
Primary outcomes: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib
Sponsor: Industry
Results posted: No
Last update: 6 August 2014

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Objectives * Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib * Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib